The Pulse of CV Disease Management
After years of delivering high-tech, high-cost treatments for cardiovascular disease, device companies are hard pressed to advance the cost-effective treatment arguments that drug companies have been touting in recent disease management programs. But in the cath lab, where price pressures are increasing, both ACS and SciMed are attempting a lateral entry into disease management through alliances with information systems companies.
You may also be interested in...
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.